Alkindi hydrocortisone granules in capsules for opening are indicated for replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).

Adrenal crisis has been reported in an infant who was switched from hydrocortisone soluble tablets to Alkindi. Acute adrenal insufficiency can occur when switching to Alkindi granules due to a potential risk of inaccurate dosing possible with other oral hydrocortisone formulations, crushed or compounded.

To prevent adrenal crisis after switching to Alkindi granules, carers should be advised to carefully observe the child during the first week for symptoms of adrenal insufficiency and to give extra doses of Alkindi granules as recommended in the product information, if the child develops symptoms of adrenal insufficiency, and seek immediate medical attention.